Enrique Valera, Jacob Berger, Umer Hassan, Tanmay Ghonge, Julia Liu, Michael Rappleye, Jackson Winter, Daniel Abboud, Zeeshan Haidry, Ryan Healey, Na-Teng Hung, Nathaniel Leung, Naif Mansury, Alexander Hasnain, Christine Lannon, Zachary Price, Karen White, Rashid Bashir
文献索引:10.1039/C8LC00033F
全文:HTML全文
Sepsis, an adverse auto-immune response to an infection often causing life-threatening complications, results in the highest mortality and treatment cost of any illness in US hospitals. Several immune biomarker levels, including Interleukin 6 (IL-6), have shown a high correlation to the onset and progression of sepsis. Currently, no technology diagnoses and stratifies sepsis progression using biomarker levels. This paper reports a microfluidic biochip platform to detect proteins in undiluted human plasma samples. The device uses a differential enumeration platform that integrates Coulter counting principles, antigen specific capture chambers, and micro size bead based immunodetection to quantify cytokines. This microfluidic biochip was validated as a potential point of care technology by quantifying IL-6 from plasma samples (n = 29) with good correlation (R2 = 0.81) and agreement (Bland–Altman) compared to controls. In combination with previous applications, this point of care platform can potentially detect cell and protein biomarkers simultaneously for sepsis stratification.
Handheld skin printer: in situ formation of planar biomateri...
2018-04-11 [10.1039/C7LC01236E] |
A simple microfluidic platform for rapid and efficient produ...
2018-04-09 [10.1039/C8LC00167G] |
Fully automated, on-site isolation of cfDNA from whole blood...
2018-04-09 [10.1039/C8LC00165K] |
Long-term C. elegans immobilization enables high resolution ...
2018-04-06 [10.1039/C7LC01185G] |
Microfluidic lung airway-on-a-chip with arrayable suspended ...
2018-04-05 [10.1039/C7LC01357D] |
首页 |
期刊大全 |
MSDS查询 |
化工产品分类 |
生物活性化合物 |
关于我们 |
免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2024 ChemSrc All Rights Reserved